PURPOSE: Exercise intolerance, associated with heart failure and death in general populations, is not well studied in survivors of childhood cancer. We examined prevalence of exercise intolerance in survivors exposed or not to cardiotoxic therapy, and associations among organ system function, exercise intolerance, and mortality. METHODS: Participants consisted of 1,041 people who had survived cancer ≥ 10 years (and had or did not have exposure to anthracyclines and/or chest-directed radiation) and 285 control subjects. Exercise intolerance was defined as peak oxygen uptake < 85% predicted from maximal cardiopulmonary exercise testing; organ functions were ascertained with imaging or clinical testing. Multivariable regression of the data was performed to compare exercise capacity between survivors exposed or unexposed to cardiotoxic therapy and control subjects, and to evaluate associations between treatment and organ function, and organ function and exercise intolerance. Propensity score methods in time-to-event analyses evaluated associations between exercise intolerance and mortality. RESULTS: Survivors (mean age ± standard deviation [SD], 35.6 ± 8.8 years) had lower mean (± SD) peak oxygen uptake (exposed: 25.74 ± 8.36 mL/kg/min; unexposed: 26.82 ± 8.36 mL/kg/min) than did control subjects (32.69 ± 7.75 mL/kg/min; P for all < .001). Exercise intolerance was present in 63.8% (95% CI, 62.0% to 65.8%) of exposed survivors, 55.7% (95% CI, 53.2% to 58.2%) of unexposed survivors, and 26.3% (95% CI, 24.0% to 28.3%) of control subjects, and was associated with mortality (hazard ratio, 3.9; 95% CI, 1.09 to 14.14). Global longitudinal strain (odds ratio [OR], 1.71; 95% CI, 1.11 to 2.63), chronotropic incompetence (OR, 3.58; 95% CI, 1.75 to 7.31); forced expiratory volume in 1 second < 80% (OR, 2.59; 95% CI, 1.65 to 4.09), and 1 SD decrease in quadriceps strength (OR, 1.49; 95% CI, 1.23 to 1.82) were associated with exercise intolerance. Ejection fraction < 53% was not associated with exercise intolerance. CONCLUSION: Exercise intolerance is prevalent among childhood cancer survivors and associated with all-cause mortality. Treatment-related cardiac (detected by global longitudinal strain), autonomic, pulmonary, and muscular impairments increased risk. Survivors with impairments may require referral to trained specialists to learn to accommodate specific deficits when engaging in exercise.
PURPOSE: Exercise intolerance, associated with heart failure and death in general populations, is not well studied in survivors of childhood cancer. We examined prevalence of exercise intolerance in survivors exposed or not to cardiotoxic therapy, and associations among organ system function, exercise intolerance, and mortality. METHODS: Participants consisted of 1,041 people who had survived cancer ≥ 10 years (and had or did not have exposure to anthracyclines and/or chest-directed radiation) and 285 control subjects. Exercise intolerance was defined as peak oxygen uptake < 85% predicted from maximal cardiopulmonary exercise testing; organ functions were ascertained with imaging or clinical testing. Multivariable regression of the data was performed to compare exercise capacity between survivors exposed or unexposed to cardiotoxic therapy and control subjects, and to evaluate associations between treatment and organ function, and organ function and exercise intolerance. Propensity score methods in time-to-event analyses evaluated associations between exercise intolerance and mortality. RESULTS: Survivors (mean age ± standard deviation [SD], 35.6 ± 8.8 years) had lower mean (± SD) peak oxygen uptake (exposed: 25.74 ± 8.36 mL/kg/min; unexposed: 26.82 ± 8.36 mL/kg/min) than did control subjects (32.69 ± 7.75 mL/kg/min; P for all < .001). Exercise intolerance was present in 63.8% (95% CI, 62.0% to 65.8%) of exposed survivors, 55.7% (95% CI, 53.2% to 58.2%) of unexposed survivors, and 26.3% (95% CI, 24.0% to 28.3%) of control subjects, and was associated with mortality (hazard ratio, 3.9; 95% CI, 1.09 to 14.14). Global longitudinal strain (odds ratio [OR], 1.71; 95% CI, 1.11 to 2.63), chronotropic incompetence (OR, 3.58; 95% CI, 1.75 to 7.31); forced expiratory volume in 1 second < 80% (OR, 2.59; 95% CI, 1.65 to 4.09), and 1 SD decrease in quadriceps strength (OR, 1.49; 95% CI, 1.23 to 1.82) were associated with exercise intolerance. Ejection fraction < 53% was not associated with exercise intolerance. CONCLUSION: Exercise intolerance is prevalent among childhood cancer survivors and associated with all-cause mortality. Treatment-related cardiac (detected by global longitudinal strain), autonomic, pulmonary, and muscular impairments increased risk. Survivors with impairments may require referral to trained specialists to learn to accommodate specific deficits when engaging in exercise.
Authors: Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt Journal: Eur Heart J Cardiovasc Imaging Date: 2015-03 Impact factor: 6.875
Authors: Gregory T Armstrong; Toana Kawashima; Wendy Leisenring; Kayla Stratton; Marilyn Stovall; Melissa M Hudson; Charles A Sklar; Leslie L Robison; Kevin C Oeffinger Journal: J Clin Oncol Date: 2014-03-17 Impact factor: 44.544
Authors: Rohit P Ojha; S Cristina Oancea; Kirsten K Ness; Jennifer Q Lanctot; D Kumar Srivastava; Leslie L Robison; Melissa M Hudson; James G Gurney Journal: Pediatr Blood Cancer Date: 2012-09-28 Impact factor: 3.167
Authors: Kirsten K Ness; Wendy M Leisenring; Sujuan Huang; Melissa M Hudson; James G Gurney; Kimberly Whelan; Wendy L Hobbie; Gregory T Armstrong; Leslie L Robison; Kevin C Oeffinger Journal: Cancer Date: 2009-05-01 Impact factor: 6.860
Authors: Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison Journal: JAMA Date: 2013-06-12 Impact factor: 56.272
Authors: Jessica M Scott; Nan Li; Qi Liu; Yutaka Yasui; Wendy Leisenring; Paul C Nathan; Todd Gibson; Saro H Armenian; Tormod S Nilsen; Kevin C Oeffinger; Kirsten K Ness; Scott C Adams; Leslie L Robison; Gregory T Armstrong; Lee W Jones Journal: JAMA Oncol Date: 2018-10-01 Impact factor: 31.777
Authors: Daniel M Green; Vikki G Nolan; Pamela J Goodman; John A Whitton; DeoKumar Srivastava; Wendy M Leisenring; Joseph P Neglia; Charles A Sklar; Sue C Kaste; Melissa M Hudson; Lisa R Diller; Marilyn Stovall; Sarah S Donaldson; Leslie L Robison Journal: Pediatr Blood Cancer Date: 2013-08-12 Impact factor: 3.167
Authors: Nickhill Bhakta; Qi Liu; Kirsten K Ness; Malek Baassiri; Hesham Eissa; Frederick Yeo; Wassim Chemaitilly; Matthew J Ehrhardt; Johnnie Bass; Michael W Bishop; Kyla Shelton; Lu Lu; Sujuan Huang; Zhenghong Li; Eric Caron; Jennifer Lanctot; Carrie Howell; Timothy Folse; Vijaya Joshi; Daniel M Green; Daniel A Mulrooney; Gregory T Armstrong; Kevin R Krull; Tara M Brinkman; Raja B Khan; Deo K Srivastava; Melissa M Hudson; Yutaka Yasui; Leslie L Robison Journal: Lancet Date: 2017-09-08 Impact factor: 79.321
Authors: Stephanie B Dixon; Eric J Chow; Lars Hjorth; Melissa M Hudson; Leontien C M Kremer; Lindsay M Morton; Paul C Nathan; Kirsten K Ness; Kevin C Oeffinger; Gregory T Armstrong Journal: Pediatr Clin North Am Date: 2020-12 Impact factor: 3.278
Authors: Samah Hayek; Tara M Brinkman; Juan C Plana; Vijaya M Joshi; Russell V Leupker; Jean B Durand; Daniel M Green; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong; Kirsten K Ness Journal: JAMA Oncol Date: 2020-08-01 Impact factor: 31.777
Authors: John L Jefferies; Wojciech M Mazur; Carrie R Howell; Juan C Plana; Kirsten K Ness; Zhenghong Li; Vijaya M Joshi; Daniel M Green; Daniel A Mulrooney; Jeffrey A Towbin; Hugo R Martinez; Jason F Goldberg; Rebecca M Howell; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Gregory T Armstrong Journal: Cancer Date: 2021-08-19 Impact factor: 6.860
Authors: Ji Young Kim; Samuel Yoo; Su Jin Yeon; Ji Hee Min; Dong-Il Kim; Ji Won Lee; Jung Woo Han; Chuhl Joo Lyu; Justin Y Jeon Journal: Support Care Cancer Date: 2021-10-02 Impact factor: 3.603
Authors: Jason F Goldberg; Kirsten K Ness; Xiaofei Chi; Aimee K Santucci; Juan Carlos Plana; Vijaya M Joshi; Russell V Luepker; Jean-Bernard Durand; Robyn E Partin; Rebecca M Howell; Carmen L Wilson; Jeffrey A Towbin; John L Jefferies; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Gregory T Armstrong Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-10-08 Impact factor: 4.090
Authors: Stephanie B Dixon; Carrie R Howell; Lu Lu; Juan C Plana; Vijaya M Joshi; Russell V Luepker; Jean B Durand; Bonnie Ky; Daniel J Lenihan; John L Jefferies; Daniel M Green; Matthew J Ehrhardt; Daniel A Mulrooney; Timothy E Folse; Robyn E Partin; Aimee K Santucci; Rebecca M Howell; Deo Kumar Srivastava; Melissa M Hudson; Leslie L Robison; Kirsten K Ness; Gregory T Armstrong Journal: Cancer Date: 2020-10-27 Impact factor: 6.921